Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Cortical functional modifications following optic neuritis.
Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.
Olfactory dysfunction in patients with multiple sclerosis.
Quality of Life Among Patients with Multiple Sclerosis Treated with Prolonged-Release Fampridine 10 Mg Tablets for Walking Impairment.
Sunshine, Sea, and Season of Birth: MS Incidence in Wales.
Does Current Portuguese Financing Model for Multiple Sclerosis Covers for Estimated Needs?
Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported.
Papers: 31 Jul 2014 - 7 Aug 2014
Further Understanding of the Immunopathology of Multiple Sclerosis: Impact on Future Treatments.
Pharmacoeconomic Aspects of Multiple Sclerosis Treatments in Iran.
Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy.
25 Hydroxyvitamin D and Cytokines in Multiple Sclerosis.
Astrocyte tissue factor controls CNS hemostasis and autoimmune inflammation.
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.
Papers: 31 Jul 2014 - 7 Aug 2014
Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study.
Information processing speed in multiple sclerosis: Past, present, and future.
Papers: 5 Feb 2016 - 12 Feb 2016
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
Static posturography across the EDSS scale in people with multiple sclerosis: a cross sectional study.
Cost-Effectiveness of Subcutaneous Interferon Beta-1A in a Sub-Population of Multiple Sclerosis Patients (Kurtzke Expanded Disability Status Scale [EDSS]: >3.5-5.0).
Improving Clinical Outcomes and Health Care Resources Utilization in Multiple Sclerosis: A Portuguese Hospital Perspective.
Episode 80 with Dr. Kaarina Kowalec on adverse MS drug reactions
Pediatric Optic Neuritis Prospective Outcomes Study.
All relapsing multiple sclerosis patients should be managed at a specialist clinic - YES.

Pages